Jazz Pharmaceuticals plc (JAZZ) — AI Analysis & Mentions

Jazz is notable because it combines a big past move with ongoing valuation discussion. The article says the stock has delivered a 122.45% 1-year total shareholder return and is still 5.3% undervalued with a fair value of $257.00. It also notes a P/E of 16.3x versus an industry average of 33.7x. That makes it interesting for investors who care about both growth and price discipline, though the drug pipeline risks mean it is not a simple story.